RT Journal Article
T1 Pluronic®/casein micelles for ophthalmic delivery of resveratrol: In vitro, ex vivo, and in vivo tests
A1 Vivero López, María
A1 Sparacino, Chiara
A1 Quelle Regaldie, Ana
A1 Sánchez Piñón, Laura Elena
A1 Candal Suárez, Eva
A1 Barreiro Iglesias, Antón
A1 Huete Toral, Fernando
A1 Carracedo Rodríguez, Juan Gonzalo
A1 Otero Casal, Ana María
A1 Concheiro Nine, Ángel
A1 Alvarez Lorenzo, Carmen
AB Ocular health may strongly benefit from the supply of antioxidant agents that counteract free radicals and reactive oxygen species responsible for long-term eye diseases. Additionally, natural antioxidants like resveratrol can inhibit bacteria growth and restore natural microbiota. However, their use is hindered by limited solubility, fast degradation, and low ocular permeability. This work aimed to overcome these limitations by preparing single and mixed micelles of Pluronic® F127 and casein that serve as resveratrol nanocarriers. Single and mixed (0.1 % casein) micelles (0.0 to −17.0 mV; 2.4 to 32.7 nm) increased 50-fold resveratrol solubility, remained stable for one month at 4 °C, withstood fast dilution, underwent sol-to-gel transitions in the 23.9–27.1 °C range, and exhibited potent antioxidant properties. All formulations successfully passed the HET-CAM assay but showed Pluronic®-casein dose-dependent toxicity in the zebrafish embryo model. Resveratrol-loaded single and mixed micelles (10–15 mM Pluronic® F127) displayed antimicrobial activity against S. aureus and P. aeruginosa. The micelles favored resveratrol accumulation in cornea and sclera, but mixed micelles showed larger lag times and provided lower amount of resveratrol permeated through sclera. In vivo (rabbit) tests confirmed the safety of resveratrol-loaded single micelles and their capability to supply resveratrol to anterior and posterior eye segments.
PB Elsevier
SN 0378-5173
YR 2022
FD 2022-10-13
LK https://hdl.handle.net/20.500.14352/73272
UL https://hdl.handle.net/20.500.14352/73272
LA eng
NO Received 10 July 2022; Received in revised form 3 October 2022; Accepted 7 October 2022
NO Fondos FEDER - European Union’s Horizon 2020
NO Ministerio de Ciencia e Innovación de España - MCIN/AEI/10.13039/ 501100011033
NO Xunta de Galicia (España)
DS Docta Complutense
RD 9 abr 2025